Suscripción a Biblioteca: Guest
Critical Reviews™ in Eukaryotic Gene Expression

Publicado 6 números por año

ISSN Imprimir: 1045-4403

ISSN En Línea: 2162-6502

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 1.6 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 2.2 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.3 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00058 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.33 SJR: 0.345 SNIP: 0.46 CiteScore™:: 2.5 H-Index: 67

Indexed in

Acceder(open in a new tab)
Más
Comprar $45.00(open in a new tab) Comprobar suscripción Descargar registro MARC(open in a new tab) Obtener permisos(open in a new tab)

miR-335-5p Targets SDC1 to Regulate the Progression of Breast Cancer

Volumen 32, Edición 6, 2022, pp. 21-31
DOI: 10.1615/CritRevEukaryotGeneExpr.2022041813
Submitted: Nov 08 2021 Accepted: Nov 15 2021 Published online: May 12 2022
Get accessGet access
Guoqing Song
Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, 110004, China
Yao Ma
Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, 110004, China
Yinghan Ma
Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, 110004, China
Pan Liu
Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, 110004, China
Lu Hou
Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, 110004, China
Zijian Xu
Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, 110004, China
Jialing Jiang
Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, 110004, China
Yang Shen
Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, 110004, China
Yanan Cao
Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, 110004, China
Yi Zhao (Corresponding author zhaoyi_9987@163.com)
Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, 110004, China

SINOPSIS

The objective of the study was to explore the role of SDC1 in breast cancer cells. Our study also investigated the regulatory relationship between SDC1 and the microRNA (miRNA) miR-335-5p as well as the impact of these two genes on the progression of breast cancer. Bioinformatic approaches were employed to analyze the differentially expressed messenger RNAs (mRNAs) and miRNAs (DE-mRNAs and DE-miRNAs) in breast cancer tissue. Then mRNA SC1 was obtained. Differentially downregulated mRNAs were intersected with target miRNAs predicted by databases, and miR-335-5p was determined as the study object. Quantitative reverse transcription polymerase chain reaction was applied to assess the expressions of SDC1 and miR-335-5p in each cell line. Next, Western blot assay was conducted to detect the protein level of SDC1 and dual-luciferase assay was performed to verify the binding relationship between miR-335-5p and SDC1. Finally, we conducted methyl thiazolyl tetrazolium (MTT), colony formation, and Transwell assays and flow cytometry to further investigate the impacts of SDC1 and miR-335-5p on the progression of breast cancer. SDC1 was significantly highly expressed while miR-335-5p was remarkably lowly expressed in human breast cancer. Silencing SDC1 in breast cancer blocked the proliferation, migration and invasion of the cells. In breast cancer, SDC1 was a target gene of miR-335-5p and silencing miR-335-5p notably increased SDC1 expression. Compared with the silence of miR-335-5p, simultaneous silences of miR-335-5p and SDC1 significantly reduced the proliferative, migratory and invasive abilities of breast cancer cells. The result revealed the interaction between miR-335-5p and SDC1 in the progression of breast cancer, which may contribute to the treatments for this cancer.

Figures

  • SDC1 is notably upregulated in breast cancer. (A) Box plots of SDC1 expressions in normal and tumor groups, in which blue boxplot represents normal group and red one indicates tumor group. (B) Survival curve of the effect of SDC1 expression on patients’ prognosis, with red line standing for high expression group and blue one representing low expression group. (C) Relative expressions of SDC1 mRNA in human mammary epithelium MCF- 10A and human breast cancer cell line BT474, MDA-MB-468, SKBR-3 and MCF7. *P < 0.05 compared with human mammary epithelium.
  • SDC1 influences the proliferation, migration and invasion. (A) Relative expression of SDC1 mRNA in transfected cells of breast cancer was assessed in qRT-PCR assay. (B) Viability of breast cancer cells was detected via MTT assay. (C) The colony numbers of transfected cells of breast cancer were confrmed in colony formation assay. (D) The migratory ability of breast cancer cells was examined in transwell migration assay (40×). (E) The invasive ability of breast cancer cells was estimated in transwell invasion assay (100×). *P < 0.05 compared with control group sh-NC.
  • SDC1 serves as a direct target of miR-335-5p in breast cancer. (A) Volcano plot of the DE-miRNAs in normal and tumor groups inTCGA-BRCA data set, with red and green dots respectively representing up- and downregulated miRNAs. (B) Venn diagram about the predicted regulatory genes in the upstream of SDC1 and downregulated DE-miRNAs. (C) Pearson correlation analysis between SDC1 and the predicted miRNAs. (D) Box plot of miR- 335-5p expressions in normal tissue and tumor tissue, in which blue indicates normal group and red indicates tumor group. (E) The potential target of miR-335-5p was predicted via bioinformatic approach. (F) Dual-luciferase assay was conducted to predict the binding relationship between miR-335-5p and SDC1 in breast cancer cells. (G) qRTPCR was applied to assess the relative expression of SDC1 mRNA after silencing miR-335-5p. (H) Western blot was employed to validate the protein expression of miR-335-5p after miR-335-5p was silenced. *P < 0.05 compared with control group NC inhibitor
  • The regulation of SDC1 by miR-335-5p influences the proliferation, migration and invasion. (A) qRT-PCR assay was launched to examine mRNA expression of SDC1 after breast cancer cells were transfected. (B) Western blot assay was performed to assess the protein expression of SDC1 after transfection of breast cancer cells. (C) MTT assay was conducted to estimate the proliferative capability of breast cancer cells. (D) Colony formation assay was implemented to determine the number of colonies. (E) Transwell migratory assay was carried out for the evaluation of the migratory capability of the cells (40×). (F) Transwell invasion assay was performed to detect the invasive capability of transfected cells of breast cancer (100×). *P < 0.05 compared with NC inhibitor+sh-NC group and the miR-335-5p inhibitor+sh-NC group
PALABRAS CLAVE: miR-335-5p, SDC1, breast cancer, proliferation, migration, invasion
REFERENCIAS

  1. Liu JC, Granieri L, Shrestha M, Wang DY, Vorobieva I, Rubie EA, Jones R, Ju Y, Pellecchia G, Jiang Z, Palmerini CA, Ben-David Y, Egan SE, Woodgett JR, Bader GD, Datti A, Zacksenhaus E. Identification of CDC25 as a common therapeutic target for triple-negative breast cancer. Cell Rep. 2018;23(1):112-26.

  2. Bambhroliya A, Van Wyhe RD, Kumar S, Debeb BG, Reddy JP, Van Laere S, El-Zein R, Rao A, Woodward WA. Gene set analysis of post-lactational mammary gland involution gene signatures in inflammatory and triple-negative breast cancer. PLoS One. 2018;13(4):e0192689.

  3. Qiu C, Huang F, Zhang Q, Chen W, Zhang H. miR-205-3p promotes proliferation and reduces apoptosis of breast cancer MCF-7 cells and is associated with poor prognosis of breast cancer patients. J Clin Lab Anal. 2019;33(8):e22966.

  4. Leonova EI, Galzitskaya OV. Structure and functions of syndecans in vertebrates. Biochemistry. 2013;78(10):1071-85.

  5. Teng YH, Aquino RS, Park PW. Molecular functions of syndecan-1 in disease. Matrix Biol. 2012;31(1):3-16.

  6. Kwon MJ, Jang B, Yi JY, Han IO, Oh ES. Syndecans play dual roles as cell adhesion receptors and docking receptors. FEBS Lett. 2012;586(16):2207-11.

  7. Lim GH, Tan PH, Jara-Lazaro AR, Thike AA, Sim WC, Yap VB, Yip GW. Syndecan-1 is a potential biomarker for triple-positive breast carcinomas in Asian women with correlation to survival. Singapore Med J. 2014;55(9):468-72.

  8. Kind S, Merenkow C, Buscheck F, Moller K, Dum D, Chirico V, Luebke AM, Hoflmayer D, Hinsch A, Jacobsen F, Gobel C, Weidemann S, Fraune C, Moller-Koop C, Hube-Magg C, Clauditz TS, Simon R, Sauter G, Wilczak W, Bawahab AA, Izbicki JR, Perez D, Marx A. Prevalence of syndecan-1 (CD138) expression in different kinds of human tumors and normal tissues. Dis Markers. 2019;2019:4928315.

  9. Watanabe A, Mabuchi T, Satoh E, Furuya K, Zhang L, Maeda S, Naganuma H. Expression of syndecans, a heparan sulfate proteoglycan, in malignant gliomas: Participation of nuclear factor-KB in upregulation of syndecan-1 expression. J Neurooncol. 2006;77(1):25-32.

  10. Fan Z, Cui H, Xu X, Lin Z, Zhang X, Kang L, Han B, Meng J, Yan Z, Yan X, Jiao S. miR-125a suppresses tumor growth, invasion and metastasis in cervical cancer by targeting STAT3. Oncotarget. 2015;6(28):25266-80.

  11. Lebanony D, Benjamin H, Gilad S, Ezagouri M, Dov A, Ashkenazi K, Gefen N, Izraeli S, Rechavi G, Pass H, Nonaka D, Li J, Spector Y, Rosenfeld N, Chajut A, Cohen D, Aharonov R, Mansukhani M. Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. J Clin Oncol. 2009;27(12):2030-7.

  12. Costinean S, Zanesi N, Pekarsky Y, Tili E, Volinia S, Heerema N, Croce CM. Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci US A. 2006;103(18):7024-9.

  13. Chen Y, Song Y, Wang Z, Yue Z, Xu H, Xing C, Liu Z. Altered expression of miR-148a and miR-152 in gastrointestinal cancers and its clinical significance. J Gastrointest Surg. 2010;14(7):1170-9.

  14. Luo L, Xia L, Zha B, Zuo C, Deng D, Chen M, Hu L, He Y, Dai F, Wu J, Wang C, Wang Y, Zhang Q. miR-335-5p targeting ICAM-1 inhibits invasion and metastasis of thyroid cancer cells. Biomed Pharmacother. 2018;106:983-90.

  15. Xu Y, Zhao F, Wang Z, Song Y, Luo Y, Zhang X, Jiang L, Sun Z, Miao Z, Xu H. MicroRNA-335 acts as a metastasis suppressor in gastric cancer by targeting Bcl-w and specificity protein 1. Oncogene. 2012;31(11):1398-407.

  16. Sun Z, Zhang Z, Liu Z, Qiu B, Liu K, Dong G. MicroRNA-335 inhibits invasion and metastasis of colorectal cancer by targeting ZEB2. Med Oncol. 2014;31(6):982.

  17. Wang X, Xiao H, Wu D, Zhang D, Zhang Z. miR-335-5p regulates cell cycle and metastasis in lung adenocarcinoma by targeting CCNB2. Onco Targets Ther. 2020;13:6255-63.

  18. Cui X, Jing X, Yi Q, Long C, Tian J, Zhu J. Clinicopathological and prognostic significance of SDC1 over-expression in breast cancer. Oncotarget. 2017;8(67): 111444-5.

  19. Qiao W, Liu H, Guo W, Li P, Deng M. Prognostic and clinical significance of syndecan-1 expression in breast cancer: A systematic review and meta-analysis. Eur J Surg Oncol. 2019;45(7):1132-7.

  20. Lu Y, Qin T, Li J, Wang L, Zhang Q, Jiang Z, Mao J. MicroRNA-140-5p inhibits invasion and angiogenesis through targeting VEGF-A in breast cancer. Cancer Gene Ther. 2017;24(9):386-92.

  21. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11-30.

  22. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74-108.

  23. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115-32.

  24. Cyr AE, Margenthaler JA. Molecular profiling of breast cancer. Surg Oncol Clin N Am. 2014;23(3):451-62.

  25. Wang CZ, Yuan P, Li Y. miR-126 regulated breast cancer cell invasion by targeting ADAM9. Int J Clin Exp Pathol. 2015;8(6):6547-53.

  26. Couchman JR, Pataki CA. An introduction to proteoglycans and their localization. J Histochem Cytochem. 2012;60(12):885-97.

  27. Conejo JR, Kleeff J, Koliopanos A, Matsuda K, Zhu ZW, Goecke H, Bicheng N, Zimmermann A, Korc M, Friess H, Buchler MW. Syndecan-1 expression is up-regulated in pancreatic but not in other gastrointestinal cancers. Int J Cancer. 2000;88(1):12-20.

  28. Shah L, Walter KL, Borczuk AC, Kawut SM, Sonett JR, Gorenstein LA, Ginsburg ME, Steinglass KM, Powell CA. Expression of syndecan-1 and expression of epidermal growth factor receptor are associated with survival in patients with nonsmall cell lung carcinoma. Cancer. 2004;101(7):1632-8.

  29. Kumar-Singh S, Jacobs W, Dhaene K, Weyn B, Bogers J, Weyler J, Van Marck E. Syndecan-1 expression in malignant mesothelioma: Correlation with cell differentiation, WT1 expression, and clinical outcome. J Pathol. 1998;186(3):300-5.

  30. Shimada K, Nakamura M, De Velasco MA, Tanaka M, Ouji Y, Miyake M, Fujimoto K, Hirao K, Konishi N. Role of syndecan-1 (CD138) in cell survival of human urothelial carcinoma. Cancer Sci. 2010;101(1):155-60.

  31. Mou T, Xie F, Zhong P, Hua H, Lai L, Yang Q, Wang J. miR-345-5p functions as a tumor suppressor in pancreatic cancer by directly targeting CCL8. Biomed Phaimacother. 2019;111:891-900.

  32. Wu J, Yuan P, Mao Q, Lu P, Xie T, Yang H, Wang C. miR-613 inhibits proliferation and invasion of breast cancer cell via VEGFA. Biochem Biophys Res Commun. 2016;478(1):274-8.

  33. Sun X, Cui M, Zhang A, Tong L, Wang K, Li K, Wang X, Sun Z, Zhang H. miR-548c impairs migration and invasion of endometrial and ovarian cancer cells via downregulation of Twist. J Exp Clin Cancer Res. 2016;35:10.

  34. Du W, Tang H, Lei Z, Zhu J, Zeng Y, Liu Z, Huang JA. miR- 335-5p inhibits TGF-beta1-induced epithelial-mesenchymal transition in non-small cell lung cancer via ROCK1. Respir Res. 2019;20(1):225.

  35. Zhang LL, Zhang LF, Guo XH, Zhang DZ, Yang F, Fan YY. Downregulation of miR-335-5p by long noncoding RNA ZEB1-AS1 in gastric cancer promotes tumor proliferation and invasion. DNA Cell Biol. 2018;37(1): 46-52.

  36. Tinay I, Tan M, Gui B, Werner L, KibelAS, Jia L. Functional roles and potential clinical application of miRNA-345-5p in prostate cancer. Prostate. 2018;78(12):927-37.

  37. Zhang D, Yang N. miR-335-5p inhibits cell proliferation, migration and invasion in colorectal cancer through downregulating LDHB. J BUON. 2019;24(3):1128-36.

  38. Liu R, Guo H, Lu S. miR-335-5p restores cisplatin sensitivity in ovarian cancer cells through targeting BCL2L2. Cancer Med. 2018;7(9):4598-609.

3484 Vistas de artículos 19 Descargas de artículos Métrica
3484 PUNTOS DE VISTA 19 DESCARGAS Google
Scholar CITAS

Artículos con contenido similar:

MiR-301b-3p Promotes the Occurrence and Development of Breast Cancer Cells via Targeting HOXA5 Critical Reviews™ in Eukaryotic Gene Expression, Vol.31, 2021, issue 3
Xianqiu Lu, Yufen Xu, Jianwen Duan, Rui Zhou
Evaluation of Potential of Long Noncoding RNA NEAT1 in Colorectal Cancer Journal of Environmental Pathology, Toxicology and Oncology, Vol.39, 2020, issue 2
Anshoo Malhotra, Hongping Cheng
miR-671-5p Promotes Cell Proliferation, Invasion, and Migration in Hepatocellular Carcinoma through Targeting ALDH2 Critical Reviews™ in Eukaryotic Gene Expression, Vol.32, 2022, issue 4
Jiansheng Luo, Zhaohui Zhang, Shengqiang Gao, Jinghua Jiang, Xiao Chen, Bin Yang
miR-1246 Promotes Laryngeal Squamous Cell Carcinoma Progression by Interacting with THBS1 Journal of Environmental Pathology, Toxicology and Oncology, Vol.41, 2022, issue 3
Yue Wang, Lifeng Wu, Shuo Pan, Jun Ma, Qixue Wang, Na Zuo
Chemotherapeutic Drugs Endow Gastric Cancer Mesenchymal Stem Cells with Stronger Tumor-Promoting Ability Journal of Environmental Pathology, Toxicology and Oncology, Vol.43, 2024, issue 1
Bo Shen, Chao Huang, Miaolin Zhu, Wei Zhu, Jiaqi Shen, Mei Wang, Zhihong Chen, Linjing Cui, Yuanyuan Zhao

Último edicion

SIAH2-Mediated Degradation of ACSL4 Inhibits the Anti-Tumor Activity of CD8+ T Cells in Hepatocellular Carcinoma Fangzheng Shu, Yuhua Shi, Xiangxiang Shan, Wenzhang Zha, Rengen Fan, Wanjiang Xue RBM15-Mediated N6-Methyl Adenosine (m6A) Modification of EZH2 Drives the Epithelial-Mesenchymal Transition of Cervical Cancer Ruixue Wang, Wenhua Tan SLC7A2-Mediated Lysine Catabolism Inhibits Immunosuppression in Triple Negative Breast Cancer Yuanyuan Sun, Yaqing Li, Chengying Jiang, Chenying Liu, Yuanming Song SIAH1 Promotes the Pyroptosis of Cardiomyocytes in Diabetic Cardiomyopathy via Regulating IκB-α/NF-κВ Signaling Jinbin Wu, Yaoming Yan PURPL Promotes M2 Macrophage Polarization in Lung Cancer by Regulating RBM4/xCT Signaling Jipeng Guo, Chongwen Gong, Hao Wang PRMT6 Promotes the Immune Evasion of Gastric Cancer by Upregulating ANXA1 Liang Xu, Fenger Zhang, Binqi Yu, Shengnan Jia, Sunfu Fan

Próximos Artículos

Fundamentals and translational applications of stem cells and biomaterials in dental, oral and craniofacial regenerative medicine Yasaman Daneshian, Eric Lewallen, Amr Badreldin, Allan Dietz , Gary Stein, Simon Cool, Hyun-Mo Ryoo, Young Dan Cho, Andre van Wijnen Inflammatory Markers Involved in the Pathogenesis of Dupuytren Contracture William Cates, Janet Denbeigh, Ralph Salvagno, Sanjeev Kakar, Andre van Wijnen, Charles Eaton SIAH1 promotes the pyroptosis of cardiomyocytes in diabetic cardiomyopathy via regulating IκB-α/NF-κB signaling Jinbin Wu, Yaoming Yan SLC7A2-mediated lysine catabolism inhibits immunosuppression in triple negative breast cancer Yuanyuan Sun, Yaqing Li, Chengying Jiang, Chenying Liu, Yuanming Song SIAH2-mediated degradation of ACSL4 inhibits the anti-tumor activity of CD8+ T cells in hepatocellular carcinoma Fangzheng Shu, Yuhua Shi, Xiangxiang Shan, Wenzhang Zha, Rengen Fan, Wanjiang Xue RBM15-mediated N6-methyl adenosine (m6A) modification of EZH2 drives the epithelial-mesenchymal transition of cervical cancer Ruixue Wang, Wenhua Tan Evidence-Based Storytelling and A Strategic Roadmap to Promote Cancer Prevention Via Adolescent HPV Vaccination in Northern New England Matthew Dugan, Gary Stein, Jan Carney, Sheila Clifford-Bova KDM4A-AS1 promotes cell proliferation, migration and invasion via the miR-4306/STX6 axis in hepatocellular carcinoma Wei Cao, Yuhan Ren, Ying Liu, Guoshu Cao, Zhen Chen, Fan Wang HDAC1-mediated downregulation of NEU1 exacerbates the aggressiveness of cervical cancer Nanzi Xie, Sisi Mei, Changlan Dai, Wei Chen Effect of miR-26b-5p on progression of acute myeloid leukemia by regulating USP48-mediated Wnt/β-catenin pathway Yu Xie, Lin Tan, Kun Wu, Deyun Li, Chengping Li
Portal Digitalde Biblioteca Digital eLibros Revistas Referencias y Libros de Ponencias Colecciones Precios y Políticas de Suscripcione Begell House Contáctenos Language English 中文 Русский Português German French Spain